{"disease":{"id":"severe-dementia","name":"severe dementia"},"drugs":{"marketed":[{"drug_id":"donepezil","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aricept","generic_name":"DONEPEZIL","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Cholinesterase Inhibitor","quality_score":75,"revenue":"800","mechanism":"Aricept works by blocking the enzyme that breaks down a key neurotransmitter in the brain, acetylcholine."},{"drug_id":"donepezil-aricept","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Donepezil (Aricept)","company_name":"University of Virginia","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"Acetylcholinesterase Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"aricept","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aricept","company_name":"Eisai Korea Inc.","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"namenda","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Namenda","company_name":"Inova Health Care Services","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"memantine","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Namenda","generic_name":"MEMANTINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Glutamate NMDA receptor; GRIN1/GRIN2A","drug_class":"N-methyl-D-aspartate Receptor Antagonist","quality_score":60,"revenue":null,"mechanism":"Namenda works by blocking the action of glutamate at the NMDA receptor, reducing excessive neural activity associated with Alzheimer's disease."},{"drug_id":"ebixa","indication_name":"Moderate to Severe Alzheimer's Type Dementia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ebixa","company_name":"Konkuk University Medical Center","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06447259","title":"Drug Burden Index is Associated With Malnutrition in Community-dwelling Dementia Patients","phase":"","overall_status":"COMPLETED","enrollment_count":415,"lead_sponsor_name":"Sultan Keskin Demircan","has_results":false},{"nct_id":"NCT01081743","title":"Effectiveness of Care Management in Alzheimer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Institut de Sante Publique, d'Epidemiologie et de Developpement","has_results":false},{"nct_id":"NCT04347668","title":"Can Virtual Reality Reduce Depression and Agitation in Older Adults With Moderate to Severe Dementia?","phase":"NA","overall_status":"UNKNOWN","enrollment_count":266,"lead_sponsor_name":"Western University, Canada","has_results":false},{"nct_id":"NCT06471660","title":"Family Caregiver Online Survey (Dementia and Swallowing Difficulties)","phase":"","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"University of Oregon","has_results":false},{"nct_id":"NCT04321889","title":"Efficacy of Defurocumarinized Bergamot in the Treatment of Agitation in Severe Dementia Patients.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":134,"lead_sponsor_name":"S.Anna Rehabilitation Institute","has_results":false},{"nct_id":"NCT04550975","title":"Advanced Cognitive Stimulation Therapy (ACST)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04555629","title":"Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03591822","title":"Pilot Study of a Robot-assisted Intervention for the Management of Care-induced Pain in Dementia","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}